Key result
Takotsubo syndrome is linked to ~41% lower MACE risk versus non-Takotsubo MINOCA.
Why the study?
Whether Takotsubo syndrome should be classified within myocardial infarction with non-obstructive coronary arteries remains controversial.
Does Takotsubo syndrome have a different clinical profile and prognosis compared to non-TTS MINOCAs?
Cohort (n=2,095)
Yes
Does Takotsubo syndrome have a different clinical profile and prognosis compared to non-TTS MINOCAs?
Takotsubo syndrome presents with a more aggressive acute phase but better long-term cardiovascular prognosis compared to non-TTS MINOCAs, supporting its classification as a distinct clinical entity.
Answers are grounded in this paper and cite their sources.
Associated lower MACE risk in Takotsubo vs non-Takotsubo MINOCA; leaves open whether this supports distinct entity classification.
Aim Whether Takotsubo syndrome (TTS) should be classified within myocardial infarction with non-obstructive coronary arteries (MINOCAs) is still controversial. The aim of this work was to evaluate the main differences between TTS and non-TTS MINOCAs. Methods and Results A cohort study based on two prospective registries: TTS from the RETAKO registry (N:1,015) and patients with non-TTS MINOCAs from contemporary records of acute myocardial infarction from five 5 national centers (N:1,080). Definitions and management recommended by the ESC were used. Survival analysis was based on the Cox regression analysis; propensity score matching (PS) was created to adjust prognostic variables. Takotsubo syndrome were more often women (85.9 vs. 51.9%; p < 0.001) and older (69.4 ± 12.5 vs. 64.5 ± 14.1 years; p < 0.001). Atrial fibrillation (AF) was more frequent in non-TTS MINOCAs (10.4 vs. 14.4%; p = 0.007). Psychiatric disorders were more prevalent in TTS (15.5 vs. 10.2%, p < 0.001). In-hospital mortality and complications were higher in TTS: 3.4 vs. 1.8%, (p = 0.015), and 25.8 vs. 11.5%, (p < 0.001). Global mortality before PS matching was 16.1% in non-TTS MINOCAs and 8.1% in TTS. Median follow-up was 32.4 months; after PS matching, TTS had fewer major adverse cardiovascular events (MACEs): hazard ratio (HR) 0.59; 95% CI 0.42–0.83. There were no differences in global mortality (HR 0.87; CI: 0.64–1.19), but TTS had lower cardiovascular mortality (HR 0.58; CI: 0.35–0.98). Conclusion Compared to the rest of MINOCAs, TTS presents a different patient profile and a more aggressive acute phase. However, its long-term cardiovascular prognosis is better. These results support that TTS should be considered a separate entity with unique characteristics and prognosis.
No takes yet. Share an insight, caveat, or question.
López‐País et al. (2022) conducted a cohort in Takotsubo syndrome and MINOCA (n=2,095). Takotsubo syndrome vs. Non-Takotsubo MINOCA was evaluated on Major adverse cardiovascular events (MACE) (HR 0.59, 95% CI 0.42-0.83, p=0.002). Takotsubo syndrome was associated with a significantly lower risk of major adverse cardiovascular events (HR 0.59) compared to non-Takotsubo MINOCA over a median follow-up of 32.4 months.
Synapse has enriched 10 related papers. Consider them for comparative context: